G1 Therapeutics, Inc.
G1 Therapeutics, Inc. (GTHX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GTHX · as of Jun 9, 2026
Key Statistics
Explore G1 Therapeutics, Inc. Data
gthx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 81.8%
The GTHX analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $4.50, representing -37.15% downside from the current price of $7.16.
Competitors & Peers
gthx competitorsGTHX
CKPT
CLYM
CTEV
ITOS
ORTXStock Performance
Full HistoryAbout G1 Therapeutics, Inc.
G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers…
what is g1 therapeutics, inc. · gthx stock overview · g1 therapeutics, inc. company profile · who is g1 therapeutics, inc. ceo · gthx NASDAQ · g1 therapeutics, inc. headquarters · g1 therapeutics, inc. business segments
About Stock Overview & Key Data
G1 Therapeutics, Inc. (GTHX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 17, 2017. As of the latest trading session, GTHX stock price is $7.16, with a market capitalization of $377.7M. The stock has returned +482.11% over the past 12 months and +130.23% year-to-date.
According to 11 Wall Street analysts, the consensus rating for G1 Therapeutics, Inc. stock is Buy, with an average 12-month price target of $4.50. In fiscal year 2023, G1 Therapeutics, Inc. reported revenue of $82.5M and net income of -$48.0M. For detailed data — including G1 Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, G1 Therapeutics, Inc. (GTHX) stock price is $7.16. The stock is traded on NASDAQ under the ticker symbol GTHX. The 52-week range is $1.08 – $7.19.